Bayer
NEWS
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).
The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.
Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.
Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind its competitors.
At the same time that Bayer AG announced it was planning to eliminate about 4,500 jobs in Germany, it is adding about 150 jobs over the next three years in Massachusetts.
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.
JOBS
IN THE PRESS